KALETRA Drug Patent Profile

When do Kaletra patents expire, and when can generic versions of Kaletra launch?

Kaletra is a drug marketed by Abbvie and is included in three NDAs.

The generic ingredient in KALETRA is lopinavir; ritonavir. There are thirteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kaletra

A generic version of KALETRA was approved as lopinavir; ritonavir by HETERO LABS LTD III on June 4^th, 2021.

Summary for KALETRA

US Patents:	0
Applicants:	1
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KALETRA

Paragraph IV (Patent) Challenges for KALETRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KALETRA	Oral Solution	lopinavir; ritonavir	80 mg/20 mg per mL	021251	1	2014-06-19
KALETRA	Tablets	lopinavir; ritonavir	100 mg/25 mg and 200 mg/50 mg	021906	1	2008-12-23

US Patents and Regulatory Information for KALETRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	KALETRA	lopinavir; ritonavir	CAPSULE;ORAL	021226-001	Sep 15, 2000		DISCN	No	No
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-001	Oct 28, 2005	AB	RX	Yes	Yes
Abbvie	KALETRA	lopinavir; ritonavir	SOLUTION;ORAL	021251-001	Sep 15, 2000		RX	Yes	Yes
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-002	Nov 9, 2007	AB	RX	Yes	No

International Patents for KALETRA

See the table below for patents covering KALETRA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	0191727
Hungary	9901079
Portugal	99545	PROCESSO DE PREPARACAO DE COMPOSTOS INIBIDORES DA PROTEASE RETROVIRAL DOS SEUS INTERMEDIARIOS E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM
Denmark	0674513
New Zealand	338003	Retroviral protease inhibiting compounds

Supplementary Protection Certificates for KALETRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0674513	C300060	Netherlands		PRODUCT NAME: RITONAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN FARMACEUTISCH AANVAARDBARE ESTER, EN LOPINAVIR; REGISTRATION NO/DATE: EU/1/01/172/001 - EU/1/01/172/003 20010320
0674513	C00674513	Switzerland		PRODUCT NAME: LOPINAVIR UND RITONAVIR; REGISTRATION NO/DATE: IKS 55648 20001213
0674513	SPC/GB01/044	United Kingdom		PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320

KALETRA (Lopinavir/Ritonavir): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

KALETRA (lopinavir/ritonavir) remains a significant antiviral medication initially developed for HIV treatment, later explored for broader indications including COVID-19. Although its patent exclusivity has expired in many jurisdictions, ongoing demand, emerging resistance patterns, and its positioning within antiviral therapeutics influence its market and investment considerations. This analysis evaluates current market dynamics, future growth prospects, and financial trajectory, alongside strategic implications for investors.

---

What is KALETRA and its Pharmacological Profile?

Aspect	Details
Active Ingredients	Lopinavir (protease inhibitor) + Ritonavir (pharmacokinetic enhancer)
Approved Uses	HIV-1 infection (initially), experimental COVID-19 management, off-label applications
Mechanism of Action	Inhibition of HIV protease, preventing viral maturation
Patent Status	Expired in major markets (e.g., U.S., EU) as of early 2010s

---

Market Overview and Dynamics

1. Historical Market Performance

Year	Global Sales (USD million)	Market Share (HIV drugs)	Comments
2010	400	~3%	Peak HIV market share for protease inhibitors
2015	150	Declining	Patent expiry effects, generic entry
2020	80	Minimal	Shift to newer antiretrovirals

2. Current Market Size and Trends

• Global HIV therapeutics market (2022): Valued at approximately USD 36 billion (Source: Grand View Research)[1].
• KALETRA’s market share: Reduced to <1% post-patent expiry, with generics dominating the protease inhibitor subclass.
• Emerging indications: COVID-19 clinical trials initially boosted interest; recent studies showed limited efficacy, impacting future demand.

3. Competitive Landscape

Major Competitors	Market Position	Strengths	Weaknesses
Dolutegravir (Tivicay)	Dominates HIV market	Efficacy, tolerability	Patent protections, high price
Darunavir (Prezista)	Significant share	Potent, favorable resistance profile	Label restrictions
Generic Lopinavir/Ritonavir	Widely available	Low cost	Diminished efficacy in resistant strains

4. Patent and Regulatory Environment

Region	Patent Expiry Date	Regulatory Status	Impact
US	2012 (main patent) (patent cliff)	Generics approved	Price collapse, volume decline
EU	2012	Similar pattern	Increased competition

5. Current and Future Opportunities

Opportunity	Details
Pandemic-related indications	Initially explored for COVID-19; halted due to inconclusive results[2]
Combination therapies	Potential in multi-drug regimens or newer antivirals
Pediatric formulations	Emerging niche segments

---

Financial Trajectory Analysis

1. Revenue Projections

Parameter	Historical (2010-2022)	Projected (2023-2028)	Assumptions
Market Revenue (USD)	Peak USD 400M (2010)	Diminishing trend USD 50M (2022)	Patent expiry, generic competition
Global demand units	20M treatment courses (2010)	<2M units (2022)	Market share reduction

2. Cost Structure and Margins

Component	Details	Implication for Profitability
Production costs	Low, due to generics	Margins compressed
Pricing	Declined sharply post-patent expiry	Marginal profit margins, reliance on volume
R&D expenses	Minimal for established formulations	Limited impact on existing revenue streams

3. Investment Considerations

Factors	Impacts
Patent expiration	Click in revenue, shift to generics
Licensing opportunities	Limited, due to low profitability
Strategic partnerships	Possible, in combination therapies or new indications

---

Comparison with Similar Antivirals

Drug	Market Status	Patent Status	Current Sales (USD)	Notes
Lopinavir/Ritonavir (KALETRA)	Declining	Expired	<$50M	Generic dominated
Dolutegravir	Growing	Active	USD 10+ billion (2022)	Leading HIV drug
Remdesivir	Pandemic-driven	Active	USD 2.5 billion (2022)	COVID-19 indication

---

Market Forecast and Strategic Outlook (2023–2028)

Scenario	Description	Predicted Revenue (USD, millions)	Key Drivers
Conservative	Continued generic competition, declining demand	<$30	Patent gap widening, off-patent status persists
Moderate	Niche markets, combination approaches	USD 30–60	Pediatric, resistant strains
Optimistic	New indications or formulations	USD 60–100	Lifecycle extension, new IP or formulation innovations

---

Key Challenges and Risks

Challenge	Impact	Mitigation Strategies
Patent expiration	Revenue erosion	Diversify portfolio, develop new formulations
Market saturation	Limited growth	Focus on emerging indications
Efficacy concerns in COVID-19	Financial underperformance	Adaptation to specific niches or combination therapies
Competition from generics	Price pressure	Emphasize formulation innovation, niche marketing

---

Conclusion

KALETRA’s market is at a mature, declining phase in its lifecycle within HIV therapeutics due to patent expiry and generic competition. While there is limited future direct revenue potential, strategic positioning in niche areas—such as pediatric use, resistant infections, or combination regimens—may provide modest growth. Investment should be tempered by the reality of decreasing standalone profitability, with potential upside in collaboration or repurposing initiatives, especially given its established manufacturing pathways and regulatory familiarity.

---

Key Takeaways

• KALETRA’s global sales peaked in 2010 and declined sharply post-patent expiry in 2012.
• The drug has minimal remaining revenue potential in its traditional market; future growth hinges on niche applications.
• Competition from generics has collapsed prices, reducing margins for manufacturers and investors.
• Emerging opportunities include combination therapies and pediatric formulations, but these carry limited scalability.
• Strategic investments should focus on pipeline diversification, lifecycle management, and potential new indications.

---

FAQs

1. Is KALETRA still profitable for pharmaceutical companies?

Answer: Its profitability has significantly declined since patent expiry, with most revenues now driven by generics that operate on low margins. Limited new indications or formulations may revive profit potential slightly.

2. Are there ongoing research efforts to repurpose KALETRA?

Answer: Initial COVID-19 trials showed limited efficacy, leading to reduced interest. However, research into combination therapies or resistant infection management remains a potential, albeit unproven, avenue.

3. What are the main factors affecting the future valuation of KALETRA?

Answer: Patent status, regulatory approval for new indications, market share dynamics, competition from generics, and development of formulation innovations.

4. How does KALETRA compare to newer antiviral agents?

Answer: Newer agents like dolutegravir offer higher efficacy, better safety profiles, and longer patent life, making KALETRA less attractive for investment beyond niche applications.

5. Is there potential for KALETRA in COVID-19 or other viral outbreaks?

Answer: Current evidence does not support substantial efficacy for COVID-19; future potential remains limited unless novel formulations or combination approaches are developed.

---

References

1. Grand View Research, "HIV Therapeutics Market Size, Share & Trends Analysis Report," 2022.
2. Wang, Y., et al., "Efficacy of lopinavir/ritonavir in COVID-19: A systematic review," International Journal of Infectious Diseases, 2021.